OpGen up 6% on planned coronavirus testing service in Europe 
 Nano cap OpGen (NASDAQ:OPGN) perks up   premarket on increased volume in response to its announcement that Ares Genetics GmbH, a subsidiary of merger partner Curetis GmbH, will collaborate with Chinese genomics outfit BGI Group on making molecular testing for the 2019-nCoV coronavirus available in Europe.

BGI was the first to sequence the genome of 2019-nCoV and has developed a polymerase chain reaction (PCR) test for its detection.